BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71. [PMID: 20724519 DOI: 10.2215/CJN.05050610] [Cited by in Crossref: 128] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Kim KB, Kim CW. Quantification of Hepatorenal Index for Computer-Aided Fatty Liver Classification with Self-Organizing Map and Fuzzy Stretching from Ultrasonography. Biomed Res Int 2015;2015:535894. [PMID: 26247023 DOI: 10.1155/2015/535894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
3 Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Diabetes 2015;64:3305-13. [PMID: 26016715 DOI: 10.2337/db14-1947] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
4 Han E, Kim MK, Jang BK, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Diabetes Metab J 2021;45:698-707. [PMID: 33517613 DOI: 10.4093/dmj.2020.0118] [Reference Citation Analysis]
5 Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, Vaughan DE, Khan SS. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int 2020;40:1111-20. [PMID: 32090434 DOI: 10.1111/liv.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sjöstedt N, Neuhoff S, Brouwer KLR. Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis. Clin Pharmacol Ther 2021;109:676-87. [PMID: 32897538 DOI: 10.1002/cpt.2037] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, Shafi T, Lazo M, Guallar E, Cho J, Gwak GY. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8:4718. [PMID: 29549269 DOI: 10.1038/s41598-018-23014-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
8 Cojocariu C, Singeap AM, Girleanu I, Chiriac S, Muzica CM, Sfarti CV, Cuciureanu T, Huiban L, Stanciu C, Trifan A. Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease. Can J Gastroenterol Hepatol 2020;2020:6630296. [PMID: 33457399 DOI: 10.1155/2020/6630296] [Reference Citation Analysis]
9 Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One. 2014;9:e88569. [PMID: 24520400 DOI: 10.1371/journal.pone.0088569] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
10 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
11 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
12 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
13 Zhang M, Lin S, Wang MF, Huang JF, Liu SY, Wu SM, Zhang HY, Wu ZM, Liu WY, Zhang DC, Hao CM, Zhu YY, Zheng MH, Wang XZ. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol 2020;20:139. [PMID: 32375660 DOI: 10.1186/s12876-020-01278-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
15 Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Mizuno N, Takemura M, Taketani H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;21:E171. [PMID: 31881781 DOI: 10.3390/ijms21010171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li AA, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2020;14:168-178. [PMID: 31195434 DOI: 10.5009/gnl19069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
17 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
18 Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S, Sonnenday CJ, Park JM. Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study. Transplant Direct 2019;5:e480. [PMID: 31579808 DOI: 10.1097/TXD.0000000000000917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, Li Q, Li N. Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. PLoS One. 2015;10:e0142808. [PMID: 26566287 DOI: 10.1371/journal.pone.0142808] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
20 Dong K, Zhang Y, Huang JJ, Xia SS, Yang Y. Shorter leucocyte telomere length as a potential biomarker for nonalcoholic fatty liver disease-related advanced fibrosis in T2DM patients. Ann Transl Med 2020;8:308. [PMID: 32355752 DOI: 10.21037/atm.2020.03.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wilechansky RM, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver Int 2019;39:1535-44. [PMID: 31033142 DOI: 10.1111/liv.14125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
22 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
26 Mikolasevic I, Orlic L, Zaputovic L, Racki S, Cubranic Z, Anic K, Devcic B, Stimac D. Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wien Klin Wochenschr 2015;127:451-8. [PMID: 25854911 DOI: 10.1007/s00508-015-0757-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
27 Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0162473. [PMID: 27627804 DOI: 10.1371/journal.pone.0162473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
28 Baars T, Sowa JP, Neumann U, Hendricks S, Jinawy M, Kälsch J, Gerken G, Rassaf T, Heider D, Canbay A. Liver parameters as part of a non-invasive model for prediction of all-cause mortality after myocardial infarction. Arch Med Sci 2020;16:71-80. [PMID: 32051708 DOI: 10.5114/aoms.2018.75678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. J Pharmacol Exp Ther 2015;352:462-70. [PMID: 25512370 DOI: 10.1124/jpet.114.220764] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
30 Cheung A, Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol 2021;14:457-65. [PMID: 34819740 DOI: 10.2147/CEG.S226130] [Reference Citation Analysis]
31 Zou W, Shi B, Zeng T, Zhang Y, Huang B, Ouyang B, Cai Z, Liu M. Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking. Front Pharmacol 2021;12:746208. [PMID: 34912216 DOI: 10.3389/fphar.2021.746208] [Reference Citation Analysis]
32 Mikolasevic I, Milic S, Racki S, Zaputovic L, Stimac D, Radic M, Markic D, Orlic L. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients. Perit Dial Int 2016;36:427-32. [PMID: 26475841 DOI: 10.3747/pdi.2014.00223] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
33 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 95.7] [Reference Citation Analysis]
34 Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D, Wensveen F, Orlic L. Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol 2016; 22(43): 9488-9505 [PMID: 27920470 DOI: 10.3748/wjg.v22.i43.9488] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 85] [Article Influence: 15.2] [Reference Citation Analysis]
35 Warden CH, Gularte-Mérida R, Fisler JS, Hansen S, Shibata N, Le A, Medrano JF, Stern JS. Leptin receptor interacts with rat chromosome 1 to regulate renal disease traits. Physiol Genomics 2012;44:1052-62. [PMID: 22968639 DOI: 10.1152/physiolgenomics.00134.2011] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Steggerda JA, Mahendraraj K, Todo T, Noureddin M. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World J Gastroenterol 2020; 26(28): 4018-4035 [PMID: 32821068 DOI: 10.3748/wjg.v26.i28.4018] [Reference Citation Analysis]
37 Shen Z, Munker S, Luo F, Ma H, Yu C, Li Y. Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age. PLoS One 2015;10:e0130614. [PMID: 26087253 DOI: 10.1371/journal.pone.0130614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Jilek JL, Frost KL, Jacobus KA, He W, Toth EL, Goedken M, Cherrington NJ. Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. Acta Pharmaceutica Sinica B 2021;11:3869-78. [DOI: 10.1016/j.apsb.2021.05.030] [Reference Citation Analysis]
39 Clarke JD, Cherrington NJ. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther 2015;151:99-106. [PMID: 25805597 DOI: 10.1016/j.pharmthera.2015.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
40 Canbay A, Sowa JP, Syn WK, Treckmann J. NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed? Visc Med. 2016;32:234-238. [PMID: 27722159 DOI: 10.1159/000446379] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
41 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Heidari Z, Gharebaghi A. Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res 2017;11:OC04-7. [PMID: 28658824 DOI: 10.7860/JCDR/2017/25931.9823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
43 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
44 Mikolasevic I, Lukenda V, Racki S, Milic S, Sladoje-Martinovic B, Orlic L. Nonalcoholic fatty liver disease (NAFLD) - a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. Clin Interv Aging 2014;9:1295-303. [PMID: 25143715 DOI: 10.2147/CIA.S65382] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
45 Deng Y, Zhao Q, Gong R. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021;14:1751-61. [PMID: 33911888 DOI: 10.2147/DMSO.S292926] [Reference Citation Analysis]
46 Behairy MA, Sherief AF, Hussein HA. Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. Int Urol Nephrol 2021. [PMID: 33675475 DOI: 10.1007/s11255-021-02815-9] [Reference Citation Analysis]
47 Samji NS, Heda R, Satapathy SK. Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . Transl Gastroenterol Hepatol 2020;5:10. [PMID: 32190778 DOI: 10.21037/tgh.2019.09.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Qin S, Wang J, Zhou C, Zhang Y, Xu Y, Wang X, Wang S. The association between a non-invasive hepatic fibrosis score and urolithiasis among non-alcoholic fatty liver disease (NAFLD) patients in China: a cross-sectional study. BMJ Open 2019;9:e027702. [PMID: 31471434 DOI: 10.1136/bmjopen-2018-027702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Han E, Lee YH. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. Diabetes Metab J 2017;41:430-7. [PMID: 29199410 DOI: 10.4093/dmj.2017.41.6.430] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
50 Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014;2014:847539. [PMID: 24729784 DOI: 10.1155/2014/847539] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
51 Laho T, Clarke JD, Dzierlenga AL, Li H, Klein DM, Goedken M, Micuda S, Cherrington NJ. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir. Biochem Pharmacol 2016;115:144-51. [PMID: 27381944 DOI: 10.1016/j.bcp.2016.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
53 Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012;36:466-471. [PMID: 23128368 DOI: 10.1159/000343885] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
54 Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680. [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680] [Cited by in Crossref: 283] [Cited by in F6Publishing: 269] [Article Influence: 35.4] [Reference Citation Analysis]
55 Ma YH. Renal dysfunction in patients with nonalcoholic fatty liver disease and risk factors. Shijie Huaren Xiaohua Zazhi 2018; 26(11): 667-672 [DOI: 10.11569/wcjd.v26.i11.667] [Reference Citation Analysis]
56 Pierre V, Johnston CK, Ferslew BC, Brouwer K, Gonzalez D. Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults. CPT Pharmacometrics Syst Pharmacol 2017;6:331-9. [PMID: 28417561 DOI: 10.1002/psp4.12185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr 2015;127:355-62. [DOI: 10.1007/s00508-014-0661-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
59 Chon YE, Kim HJ, Choi YB, Hwang SG, Rim KS, Kim MN, Lee JH, Ha Y, Lee MJ. Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease. Sci Rep. 2020;10:8996. [PMID: 32488147 DOI: 10.1038/s41598-020-65940-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Petta S, Tuttolomondo A, Gagliardo C, Zafonte R, Brancatelli G, Cabibi D, Cammà C, Di Marco V, Galvano L, La Tona G. The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. Medicine (Baltimore). 2016;95:e3446. [PMID: 27100443 DOI: 10.1097/md.0000000000003446] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
61 Cao Y, Deng Y, Wang J, Zhao H, Zhang J, Xie W. The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Ther Adv Chronic Dis 2021;12:20406223211048649. [PMID: 34777740 DOI: 10.1177/20406223211048649] [Reference Citation Analysis]